Duvelisib was the next PI3K inhibitor accredited via the FDA, also according to a phase III randomized trial.130 The efficacy and protection profile of the drug appear comparable with These of idelalisib, if not slightly advantageous. About alternate BTK inhibitors, there are many items in advanceme